Welcome to our dedicated page for Aldeyra Therapeutics news (Ticker: ALDX), a resource for investors and traders seeking the latest updates and insights on Aldeyra Therapeutics stock.
Aldeyra Therapeutics develops investigational therapies for immune-mediated diseases, with news centered on its RASP modulator platform and late-stage ocular programs. Company updates commonly cover reproxalap, a RASP modulator for dry eye disease and allergic conjunctivitis; ADX-2191, an intravitreal methotrexate formulation for primary vitreoretinal lymphoma and retinitis pigmentosa; and next-generation RASP modulators including ADX-248 and ADX-246 for systemic and retinal immune-mediated diseases.
Recurring developments include FDA interactions on the reproxalap New Drug Application, clinical and preclinical results, pipeline prioritization, manufacturing and regulatory disclosures, and research-and-development presentations. Aldeyra also reports conference participation and corporate updates tied to its Nasdaq-listed biotechnology issuer profile.
Aldeyra Therapeutics has completed enrollment in its Phase 2 clinical trial of ADX-2191, a methotrexate injection, for treating retinitis pigmentosa, a rare genetic eye disease. This trial involves eight patients with rhodopsin gene mutations receiving intravitreal doses for three months. The primary focus is on safety, while secondary endpoints assess changes in visual acuity and retinal function. The company aims to report top-line results in the first half of 2023. ADX-2191 has received orphan drug designation from the FDA, addressing an unmet medical need affecting over one million patients worldwide.
Aldeyra Therapeutics (Nasdaq: ALDX) reported significant developments and financial results for 2022, with key highlights including the Priority Review Designation for ADX-2191 to treat primary vitreoretinal lymphoma, with a PDUFA date set for June 21, 2023. The NDA for reproxalap to treat dry eye disease has a PDUFA date of November 23, 2023. Financially, cash and marketable securities totaled $174.3 million as of December 31, 2022. Despite a net loss of $62 million for the year, Aldeyra believes its current financial resources will fund operations into the second half of 2024, supporting ongoing clinical trials and potential commercial launches.
Aldeyra Therapeutics (ALDX) announced the FDA's acceptance of the New Drug Application (NDA) for ADX-2191, aimed at treating primary vitreoretinal lymphoma. The FDA granted Priority Review, with a PDUFA date set for June 21, 2023. ADX-2191 could become the first FDA-approved treatment for this rare cancer, with no approved alternatives currently available. The NDA is supported by extensive literature and recent Phase 3 GUARD Trial data, showing no serious adverse safety signals. Aldeyra plans to launch ADX-2191 in the U.S. in the second half of 2023, pending FDA approval.
Aldeyra Therapeutics, Inc. (ALDX) will host a conference call on March 9, 2023, at 8:00 a.m. ET to discuss its financial results for the year ended December 31, 2022, and recent corporate highlights. The call is accessible to both domestic and international callers with dedicated dial-in numbers. Investors can also access a live audio webcast of the conference through Aldeyra’s website, where the event will remain archived for 90 days. Aldeyra is a clinical-stage biotechnology company focused on therapies for immune-mediated diseases, with key product candidates under FDA review.
Aldeyra Therapeutics (Nasdaq: ALDX) announced positive top-line results from a 12-month safety trial of reproxalap for dry eye disease. The trial, involving 447 patients, showed no treatment-related serious adverse events and similar ocular safety metrics across both reproxalap and vehicle groups. Post-hoc analysis indicated that reproxalap significantly improved distance visual acuity by approximately 37%, marking a potential breakthrough as the first topical treatment to demonstrate such improvement. With over 2,300 patients tested, reproxalap continues to show a promising safety profile, reinforcing its viability for regulatory review.
Aldeyra Therapeutics (Nasdaq: ALDX) announced the advancement of two new drug candidates, ADX-246 and ADX-248, into clinical testing for treating systemic immune-mediated diseases and geographic atrophy, respectively. These candidates are part of Aldeyra's innovative drug discovery platform targeting RASP modulation. Pending completion of FDA requirements, a Phase 1 trial for ADX-246 and a Phase 1/2 trial for ADX-248 are expected to start in late 2023 or early 2024. With over 100 million people in the U.S. facing diseases linked to systemic inflammation, these developments underscore Aldeyra's leadership in this therapeutic area.
Aldeyra Therapeutics (NASDAQ: ALDX) announced the initiation of Phase 2 clinical trials for ADX-629, targeting minimal change disease and Sjögren-Larsson Syndrome. The minimal change disease trial will now also include idiopathic nephrotic syndrome. Additionally, a new trial for atopic dermatitis has commenced. Aldeyra's recent credit facility amendment extends its cash runway into the second half of 2024, positioning the company to advance its product candidates, including reproxalap and ADX-2191, if approved. Top-line results are expected in 2023, showcasing the company's commitment to developing innovative treatment options.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) has announced that Dr. Todd C. Brady, President and CEO, will participate in a fireside chat at the SVB Securities Global Biopharma Conference, taking place virtually from February 14-16, 2023. Dr. Brady's discussion with Senior Research Analyst Marc Goodman is scheduled for 10:00 a.m. ET on February 16. Investors can watch the live webcast through Aldeyra's Investors & Media section and the event will be archived for 90 days. Aldeyra is focused on developing therapies for immune-mediated diseases, including potential treatments for dry eye disease and primary vitreoretinal lymphoma.
Aldeyra Therapeutics announced the acceptance of its New Drug Application (NDA) for topical ocular reproxalap by the FDA, with a PDUFA date of November 23, 2023.
The drug aims to address dry eye disease, a condition affecting over 39 million adults in the U.S. The NDA is backed by positive results from five clinical trials, indicating reproxalap's potential for rapid and durable effects. The drug has shown no significant safety concerns in more than 2,000 patients, though mild irritation at the application site was noted. Aldeyra is optimistic about the drug's efficacy and the unmet needs in dry eye disease treatment.
Aldeyra Therapeutics (NASDAQ: ALDX) announced the submission of a New Drug Application (NDA) for ADX-2191, a methotrexate injection for treating primary vitreoretinal lymphoma, a rare cancer with no approved therapy. This NDA is backed by safety data from the Phase 3 GUARD Trial, which showed ADX-2191 was well tolerated, with fewer adverse events compared to compounded methotrexate. The company has also requested Priority Review from the FDA to expedite the process. ADX-2191 also holds FDA Orphan Drug Designation, highlighting its potential significance in treating this condition.